About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Rb1
RB transcriptional corepressor 1
MGI:97874
169 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Apaf1tm1Mak/Apaf1tm1Mak
Rb1tm1Tyj/Rb1tm1Tyj
Tg(Rb1)1Blg/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 		increased cochlear hair cell number J:98518
increased vestibular hair cell number J:98518
Atrxtm1Rjg/Atrxtm1Rjg
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1 		decreased tumor latency J:329449
increased osteosarcoma incidence J:329449
Atrxtm1Rjg/Y
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1 		decreased tumor latency J:329449
increased osteosarcoma incidence J:329449
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
involves: 129 * 129P2/OlaHsd * FVB/N 		abnormal pulmonary neuroendocrine body morphology J:190366
increased lung small cell carcinoma incidence J:190366
increased thyroid tumor incidence J:190366
postnatal lethality J:190366
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu
involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N 		abnormal pulmonary neuroendocrine body morphology J:190366
increased lung small cell carcinoma incidence J:190366
increased metastatic potential J:190366
increased thyroid tumor incidence J:190366
postnatal lethality J:190366
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Rb1tm2Brn/Rb1tm2Brn
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJaeSor * C57BL/6 * CBA 		normal immune system phenotype J:192031
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Rb1tm2Brn/Rb1tm2Brn
Tg(Mx1-cre)1Cgn/0
involves: 129 * C57BL/6 * CBA 		decreased double-positive T cell number J:192031
decreased T cell proliferation J:192031
thymus hypoplasia J:192031
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Rb1tm1Tyj/Rb1+
Tg(Rb1)1Blg/0
involves: 129S2/SvPas 		abnormal xiphoid process morphology J:65679
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Rb1tm1Tyj/Rb1tm1Tyj
Tg(Rb1)1Blg/0
involves: 129S2/SvPas 		abnormal deltoid tuberosity morphology J:65679
abnormal muscle physiology J:65679
abnormal myogenesis J:65679
abnormal posture J:65679
abnormal scapula morphology J:65679
abnormal skeletal muscle fiber morphology J:65679
abnormal sternocostal joint morphology J:65679
abnormal sternum ossification J:65679
abnormal xiphoid process morphology J:65679
absent deltoid tuberosity J:65679
decreased length of long bones J:65679
fragile skeleton J:65679
hemorrhage J:65679
hunched posture J:65679
polyploidy J:65679
Cdkn1btm1Jro/Cdkn1btm1Jro
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N 		abnormal tumor pathology J:318035
decreased tumor growth/size J:318035
normal growth/size/body region phenotype J:318035
increased osteosarcoma incidence J:318035
increased tumor-free survival time J:318035
normal reproductive system phenotype J:318035
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N 		decreased tumor latency J:269943
increased osteosarcoma incidence J:269943
increased tumor growth/size J:269943
premature death J:269943
E2f1tm1Meg/E2f1tm1Meg
Rb1tm1Tyj/Rb1tm1Tyj
Tg(Rb1)1Blg/0
involves: 129S2/SvPas * 129S4/SvJae 		abnormal cell cycle J:65679
abnormal muscle physiology J:65679
abnormal skeletal muscle fiber morphology J:65679
hunched posture J:65679
hyporesponsive to tactile stimuli J:65679
polyploidy J:65679
E2f1tm1Meg/E2f1tm1Meg
Rb1tm2.1Fad/Rb1tm2.1Fad
involves: 129S4/SvJae * C57BL/6 		normal cellular phenotype J:215358
normal neoplasm J:215358
postnatal lethality, incomplete penetrance J:215358
E2f1tm1Njd/E2f1+
Rb1tm1Tyj/Rb1+
either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6) 		increased thyroid adenoma incidence J:47108
increased tumor incidence J:47108
premature death J:47108
E2f1tm1Njd/E2f1+
Rb1tm1Tyj/Rb1tm1Tyj
either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6) 		prenatal lethality, complete penetrance J:47108
E2f1tm1Njd/E2f1tm1Njd
Rb1tm1Tyj/Rb1+
either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6) 		abnormal thyroid gland morphology J:47108
adrenal medulla hyperplasia J:47108
increased hemangioma incidence J:47108
increased pituitary gland tumor incidence J:47108
increased thyroid adenoma incidence J:47108
premature death J:47108
uterine hemorrhage J:47108
E2f1tm1Njd/E2f1tm1Njd
Rb1tm1Tyj/Rb1tm1Tyj
either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6) 		prenatal lethality, complete penetrance J:47108
E2f4tm1Lees/E2f4+
Rb1tm1Tyj/Rb1+
involves: 129S2/SvPas * C57BL/6 		increased pituitary gland tumor incidence J:81082
increased thyroid tumor incidence J:81082
premature death J:81082
E2f4tm1Lees/E2f4tm1Lees
Rb1tm1Tyj/Rb1+
involves: 129S2/SvPas * C57BL/6 		decreased tumor incidence J:81082
increased susceptibility to infection J:81082
premature death J:81082
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Tg(Gfap-cre)2Brn/0
either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased pituitary gland tumor incidence J:187257
normal neoplasm J:187257
premature death J:187257
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N) 		increased carcinoma incidence J:187257
increased medulloblastoma incidence J:187257
increased pituitary gland tumor incidence J:187257
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1+
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate gland tumor incidence J:307910
premature death J:307910
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased metastatic potential J:307910
increased prostate gland tumor incidence J:307910
premature death J:307910
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB 		normal neoplasm J:204385
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N 		increased nervous system tumor incidence J:204385
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N 		increased nervous system tumor incidence J:204385
Kdm5atm1.1Kael/Kdm5a+
Rb1tm1Tyj/Rb1+
involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N 		increased pituitary gland tumor incidence J:175625
increased thyroid tumor incidence J:175625
Kdm5atm1.1Kael/Kdm5a+
Rb1tm1Tyj/Rb1tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N 		embryonic lethality, complete penetrance J:175625
increased fibroblast proliferation J:175625
Kdm5atm1.1Kael/Kdm5atm1.1Kael
Rb1tm1Tyj/Rb1+
involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N 		increased pituitary gland tumor incidence J:175625
increased thyroid tumor incidence J:175625
premature death J:175625
Kdm5atm1.1Kael/Kdm5atm1.1Kael
Rb1tm1Tyj/Rb1tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N 		abnormal cell differentiation J:175625
normal cellular phenotype J:175625
embryonic lethality, complete penetrance J:175625
Krastm4Tyj/Kras+
Rb1tm3Tyj/Rb1tm3Tyj
involves: 129S4/SvJae 		abnormal bronchiole morphology J:147590
abnormal tumor morphology J:147590
increased lung adenocarcinoma incidence J:147590
increased lung tumor incidence J:147590
premature death J:147590
Men1tm1.1Ctre/Men1+
Rb1tm1Tyj/Rb1+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N 		increased adrenal gland tumor incidence J:133299
increased metastatic potential J:133299
increased pancreas tumor incidence J:133299
increased parathyroid gland tumor incidence J:133299
increased pheochromocytoma incidence J:133299
increased pituitary adenohypophysis tumor incidence J:133299
increased pituitary melanotroph tumor incidence J:133299
increased thyroid C-cell carcinoma incidence J:133299
premature death J:133299
Msh2tm1Whl/Msh2tm1Whl
Rb1tm1Brd/Rb1+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal definitive hematopoiesis J:79016
abnormal tumor morphology J:79016
increased gastrointestinal tumor incidence J:79016
increased lymphoblastic lymphoma incidence J:79016
increased pheochromocytoma incidence J:79016
increased pituitary adenohypophysis tumor incidence J:79016
increased pituitary melanotroph tumor incidence J:79016
increased skin tumor incidence J:79016
increased thyroid C-cell carcinoma incidence J:79016
increased tumor incidence J:79016
premature death J:79016
Msh2tm1Whl/Msh2tm1Whl
Rb1tm1Brd/Rb1tm1Brd
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J 		abnormal definitive hematopoiesis J:79016
Nell1tm1Kuv/Nell1tm1Kuv
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
involves: 129 * FVB/NJ 		abnormal tumor morphology J:326989
abnormal tumor vascular morphology J:326989
decreased osteosarcoma incidence J:326989
increased tumor-free survival time J:326989
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N 		increased cell migration J:234128
increased osteosarcoma incidence J:234128
premature death J:234128
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N 		increased osteosarcoma incidence J:234128
premature death J:234128
Prmt1tm1a(EUCOMM)Wtsi/Prmt1tm1a(EUCOMM)Wtsi
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1 		decreased osteosarcoma incidence J:245660
increased tumor latency J:245660
increased tumor-free survival time J:245660
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1 		increased osteosarcoma incidence J:245660
premature death J:245660
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:307910
premature death J:307910
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
Trp53tm1Tyj/Trp53tm1Tyj
129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw 		decreased apoptosis J:102483
increased colon adenoma incidence J:102483
increased intestinal adenocarcinoma incidence J:102483
increased lymphoma incidence J:102483
increased teratoma incidence J:102483
increased testicular teratoma incidence J:102483
intestinal ulcer J:102483
premature death J:102483
weight loss J:102483
Rb1tm1Brd/Rb1+
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6J 		premature death J:79016
Rb1tm1Brd/Rb1+
Rr70tm1Alb/Rr70+
involves: 129S7/SvEvBrd * C57BL/6 		abnormal DNA methylation J:113402
abnormal imprinting J:113402
Rb1tm1Fad/Rb1+
Tg(KRT14-HPV16E7)2304Plam/0
involves: 129 * C57BL/6 * FVB 		abnormal epidermis suprabasal layer morphology J:101623
normal cellular phenotype J:101623
Rb1tm1Fad/Rb1tm1Fad
Tg(KRT14-HPV16E7)2304Plam/0
involves: 129 * C57BL/6 * FVB 		abnormal epidermis suprabasal layer morphology J:101623
normal cellular phenotype J:101623
Rb1tm1Fad/Rb1tm1Fad
Tg(MMTVTGFB1)46Hlm/?
involves: 129 * C57BL/6 * DBA/2 		mammary gland hyperplasia J:151417
Rb1tm1Tyj/Rb1+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 		abnormal tumor morphology J:19542
bronchial epithelial hyperplasia J:19542
increased leiomyosarcoma incidence J:19542
increased pancreatic islet cell carcinoma incidence J:19542
increased pituitary melanotroph tumor incidence J:19542
increased sarcoma incidence J:19542
increased thyroid tumor incidence J:19542
increased tumor incidence J:19542
premature death J:19542
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1+
involves: 129S2/SvPas * C57BL/6 		decreased tumor-free survival time J:34058
increased pituitary gland tumor incidence J:34058
Rb1tm1Tyj/Rb1+
Rbl1tm1Tyj/Rbl1tm1Tyj
involves: 129S2/SvPas * C57BL/6 		abnormal perineum morphology J:34058
abnormal retina morphology J:34058
abnormal retina photoreceptor morphology J:34058
decreased body size J:34058
decreased body weight J:34058
decreased tumor-free survival time J:34058
distended abdomen J:34058
increased pituitary gland tumor incidence J:34058
postnatal growth retardation J:34058
postnatal lethality, incomplete penetrance J:34058
premature death J:34058
vagina atresia J:34058
Rb1tm1Tyj/Rb1+
Smarca4tm1Mag/Smarca4+
involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1 		increased pituitary gland tumor incidence J:132091
premature death J:132091
Rb1tm1Tyj/Rb1+
Tg(S100b-v-erbB)4496Waw/0
involves: 129S2/SvPas * C57BL/6J * DBA/2J * FVB/N 		increased glioma incidence J:82649
Rb1tm1Tyj/Rb1+
Tg(Th-MYCN)41Waw/0
involves: 129S2/SvPas * BALB/c * C57BL/6J 		increased neuroblastoma incidence J:41126
Rb1tm1Tyj/Rb1+
Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
involves: 129P2/OlaHsd * C57BL/6 		increased pituitary gland tumor incidence J:189317
increased thyroid tumor incidence J:189317
increased tumor incidence J:189317
Rb1tm1Tyj/Rb1tm1Tyj
Rbl1tm1Mru/Rbl1tm1Mru
involves: 129S2/SvPas * 129S4/SvJae * BALB/c * C57BL/6 		increased neuronal precursor cell number J:92520
Rb1tm1Tyj/Rb1tm1Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
involves: 129S2/SvPas * C57BL/6 		abnormal vitelline vasculature morphology J:34058
decreased embryo size J:34058
embryonic lethality during organogenesis, incomplete penetrance J:34058
increased apoptosis J:34058
normal muscle phenotype J:34058
pale yolk sac J:34058
Rb1tm1Tyj/Rb1tm1Tyj
Tg(Rb1)1Blg/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas 		abnormal cell cycle J:65679
abnormal muscle physiology J:65679
abnormal retina apoptosis J:65679
abnormal skeletal muscle fiber morphology J:65679
hunched posture J:65679
hyporesponsive to tactile stimuli J:65679
polyploidy J:65679
postnatal lethality J:65679
Rb1tm1Tyj/Rb1tm1Tyj
Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
involves: 129P2/OlaHsd * C57BL/6 		increased cell proliferation J:189317
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		abnormal retina morphology J:120315
increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		abnormal eye posterior chamber morphology J:120315
abnormal retina morphology J:120315
decreased retina photoreceptor cell number J:120315
increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		abnormal eye anterior chamber morphology J:120315
abnormal eye posterior chamber morphology J:120315
abnormal retina morphology J:120315
increased retinoblastoma incidence J:120315
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Tyj
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL 		abnormal cell proliferation J:120315
abnormal eye anterior chamber morphology J:120315
abnormal eye posterior chamber morphology J:120315
increased retinoblastoma incidence J:120315
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd 		abnormal tumor pathology J:86077
increased lung adenocarcinoma incidence J:86077
increased lung small cell carcinoma incidence J:86077
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * FVB/N 		increased osteosarcoma incidence J:234128
premature death J:234128
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Htr/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(En2-cre)22Alj/0
involves: 129P2/OlaHsd * CD-1 		normal cellular phenotype J:83783
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Htr/Rbl1+
Tg(En2-cre)22Alj/0
involves: 129P2/OlaHsd * CD-1 		abnormal cerebellum vermis morphology J:83783
abnormal neuronal precursor proliferation J:83783
ataxia J:83783
cerebellum hypoplasia J:83783
increased neuron apoptosis J:83783
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Htr/Rbl1tm1Htr
Tg(En2-cre)22Alj/0
involves: 129P2/OlaHsd * CD-1 		abnormal cerebellar cortex morphology J:83783
abnormal cerebellum vermis morphology J:83783
abnormal neuronal precursor proliferation J:83783
abnormal Purkinje cell morphology J:83783
ataxia J:83783
thin cerebellar molecular layer J:83783
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Htr/Rbl1tm1Htr
Tg(Pcp2-cre)756Mro/0
involves: 129P2/OlaHsd * FVB 		abnormal Purkinje cell morphology J:83783
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
involves: 129 * 129S2/SvPas * 129S4/SvJae 		hematuria J:217195
increased urinary bladder carcinoma incidence J:217195
Rb1tm2Brn/Rb1tm2Brn
Rbl2tm1Tyj/Rbl2tm1Tyj
Tg(Myh6-cre)2182Mds/Tg(Myh6-cre)2182Mds
involves: 129 * 129S2/SvPas * FVB/N 		abnormal myocardial fiber physiology J:97589
decreased heart left ventricle muscle contractility J:97589
decreased heart rate J:97589
dilated heart left ventricle J:97589
edema J:97589
enlarged heart J:97589
increased myocardial fiber size J:97589
premature death J:97589
respiratory distress J:97589
Rb1tm2Brn/Rb1tm2Brn
Tg(KRT14-cre)8Brn/0
Tg(KRT5-Akt1*)Jmpa/0
involves: 129 * C57BL/6 * DBA/2 * DBA/2J * FVB/N 		abnormal oral mucosa morphology J:144831
increased tumor incidence J:144831
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53+
Tg(Rbp3-cre)1Brn/0
involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N 		abnormal tumor morphology J:77982
increased tumor incidence J:77982
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53tm1Brd
Tg(Gfap-cre)2Brn/0
involves: 129 * 129S7/SvEvBrd * FVB/N 		abnormal gait J:61961
ataxia J:61961
circling J:61961
impaired balance J:61961
increased medulloblastoma incidence J:61961
tremors J:61961
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd 		increased lung adenocarcinoma incidence J:86077, J:157319
increased lung small cell carcinoma incidence J:86077, J:157319
increased lung tumor incidence J:157319
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd 		abnormal tumor pathology J:86077
decreased tumor-free survival time J:84345
increased lung carcinoma incidence J:86077
increased lung small cell carcinoma incidence J:86077, J:157319
increased lung tumor incidence J:157319
increased metastatic potential J:84345
increased ovarian carcinoma incidence J:84345
increased ovary tumor incidence J:84345
increased thyroid carcinoma incidence J:86077, J:157319
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
involves: 129 * 129P2/OlaHsd * FVB/NJ 		decreased tumor-free survival time J:326989
increased osteosarcoma incidence J:326989
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * FVB/N 		increased osteosarcoma incidence J:234128
premature death J:234128
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
involves: 129 * 129P2/OlaHsd * FVB/N 		increased carcinoma incidence J:187257
increased medulloblastoma incidence J:187257
increased papilloma incidence J:187257
increased pituitary gland tumor incidence J:187257
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
involves: 129P2/OlaHsd * FVB/N 		increased medulloblastoma incidence J:61961
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn 		chromosomal instability J:165292
increased carcinoma incidence J:165292
increased lung tumor incidence J:165292
increased mammary gland tumor incidence J:165292
increased squamous cell carcinoma incidence J:165292
increased tumor growth/size J:165292
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Ren-cre)#Kwg/0
involves: 129 * 129P2/OlaHsd 		decreased body weight J:216559
decreased tumor-free survival time J:216559
increased circulating glucagon level J:216559
increased glucagonoma incidence J:216559
increased metastatic potential J:216559
increased pancreatic islet cell carcinoma incidence J:216559
increased sarcoma incidence J:216559
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Lejo/Trp53tm1Lejo
involves: 129 		abnormal lung morphology J:187012
increased lung small cell carcinoma incidence J:187012
premature death J:187012
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N 		increased metastatic potential J:136693
increased osteosarcoma incidence J:136693
premature death J:136693
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1 		decreased tumor-free survival time J:318885
increased osteosarcoma incidence J:318885
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N 		increased metastatic potential J:136693
increased osteosarcoma incidence J:136693
premature death J:136693
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1 		decreased osteosarcoma incidence J:318885
increased tumor-free survival time J:318885
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2tm4.1Skn
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1 		decreased osteosarcoma incidence J:318885
increased tumor-free survival time J:318885
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 		increased hepatocellular carcinoma incidence J:177573
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Tg(Nes-cre)1Atp/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N 		abnormal retina apoptosis J:91406
abnormal retina morphology J:91406
postnatal lethality J:91406
Rb1tm3Tyj/Rb1tm3Tyj
Rbl1tm1Tyj/Rbl1tm1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
involves: 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N 		abnormal retina morphology J:119919
increased retinoblastoma incidence J:119919
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm1Tyj/Rbl2tm1Tyj
Tg(Nes-cre)1Atp/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N 		abnormal retina apoptosis J:91406
decreased tumor-free survival time J:91406
increased retinoblastoma incidence J:91406
transmission ratio distortion J:91406
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
Tg(Pax6-cre,GFP)2Pgr/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N 		abnormal amacrine cell morphology J:119919
abnormal retina horizontal cell morphology J:119919
abnormal retina morphology J:119919
abnormal retina neuronal layer morphology J:119919
absent retina bipolar cells J:119919
absent retina ganglion cell J:119919
decreased retina cone cell number J:119919
increased retina apoptosis J:119919
increased retinoblastoma incidence J:119919
premature death J:119919
retina hypoplasia J:119919
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae 		increased lung small cell carcinoma incidence J:160148
increased lung tumor incidence J:160148
premature death J:160148
Rb1tm3Tyj/Rb1tm3Tyj
Tg(KRT14-cre)8Brn/0
Tg(KRT14-HPV16E7)2304Plam/0
involves: 129S4/SvJae * C57BL/6 * FVB 		abnormal epidermis stratum granulosum morphology J:101623
abnormal epidermis suprabasal layer morphology J:101623
epidermal hyperplasia J:101623
Rb1tm3Tyj/Rb1tm3Tyj
Tg(KRT14-HPV16E7)2304Plam/0
involves: 129S4/SvJae * C57BL/6 * FVB 		abnormal epidermis stratum granulosum morphology J:101623
abnormal epidermis suprabasal layer morphology J:101623
Rb1tm3Tyj/Rb1tm3Tyj
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
Tg(tetO-RNAi:Trp53)ASlowe/0
involves: 129S4/SvJae * C57BL/6 * CD-1 		increased circulating alkaline phosphatase level J:199542
increased metastatic potential J:199542
increased osteosarcoma incidence J:199542
premature death J:199542
Rb1tm3Tyj/Rb1tm3Tyj
Tg(tetO-MYC)36aBop/0
Tg(Cebpb-tTA)5Bjd/0
involves: FVB/N * NMRI 		decreased tumor-free survival time J:172430
increased hepatocellular carcinoma incidence J:172430
increased liver tumor incidence J:172430
polyploidy J:172430
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N 		increased metastatic potential J:136693
increased osteosarcoma incidence J:136693
premature death J:136693
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae 		increased lung small cell carcinoma incidence J:160148
increased lung tumor incidence J:160148
premature death J:160148
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1 		increased hibernoma incidence J:199542
increased metastatic potential J:199542
increased osteosarcoma incidence J:199542
premature death J:199542
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N 		increased metastatic potential J:318035
increased osteosarcoma incidence J:136693, J:318035
increased tumor incidence J:136693
postnatal growth retardation J:136693
premature death J:136693, J:318035
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1 		increased osteosarcoma incidence J:329449
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Atp/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N 		abnormal eye morphology J:91406
abnormal retina morphology J:91406
decreased retina photoreceptor cell number J:91406
decreased tumor-free survival time J:91406
increased pituitary gland tumor incidence J:91406
increased retina apoptosis J:91406
thin retina outer nuclear layer J:91406
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory